Rituximab (RTX)

DRUG3 trials

Sponsors

Incyte Corporation, Chinese SLE Treatment And Research Group, Inge Marie Svane

Conditions

Diffuse Large B-cell LymphomaImmune-Related Adverse EventsRheumatoid Arthritis Associated Interstitial Lung Disease

Phase 1

Rituximab for Treatment of Checkpoint Inhibitor Induced Immune-related Adverse Events

Not yet recruitingNCT07694414

Inge Marie SvaneImmune-Related Adverse Events

Start: 2026-08-01End: 2028-12-01Target: 25Updated: 2026-07-22

Phase 2

A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

CompletedNCT02763319

Incyte CorporationDiffuse Large B-cell Lymphoma

Start: 2016-11-28End: 2024-06-21Updated: 2025-07-17

Phase 4

Treatment Strategy for Patients With RA-ILD

Not yet recruitingNCT07643038

Chinese SLE Treatment And Research GroupRheumatoid Arthritis Associated Interstitial Lung Disease

Start: 2026-09-20End: 2029-07-31Target: 204Updated: 2026-09-03

Related Papers

Antibodies to watch in 2020.

2020-01-01328 citations

Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.

2018-05-01104 citations

B-MIND: MOR208 plus bendamustine (BEN) versus rituximab (RTX) plus BEN in patients with relapsed or refractory (R-R) diffuse large B-cell lymphoma (DLBCL): An open-label, randomized phase II/III trial.

Journal of Clinical Oncology2017-05-202 citations